Here is another good news/bad news column about the 112th Congress.

The Cold War is an increasingly distant memory in American military minds, except in the minds of the arms control community, and in particular those who seek the elimination of nuclear weapons. Alas, our president is a member in good standing of this community—indeed, an organizer.So, too, it...

With fakes of the cancer drug Avastin popping up in U.S. clinics in the past few months, patients are naturally worried about whether their medicines are safe.  Considering eighty percent of the ingredients in U.S. medicines come from overseas – mostly from China and India because their products are generally...

The Medicaid drug program wasted $329 million nationwide in 2009 from states all too frequently reimbursing for a version of a drug that is more costly than another product with the exact same active ingredient, dose, form and bottle size.

In an attempt to protect poor, uninsured and underinsured Americans from unsafe drugs, we are making sure that some go without drugs completely. It is time the law was changed.

Evidence from numerous studies shows that emerging markets have far more poor quality drugs than western markets. There are many reasons for this, but one reason, investigated in this paper, is the possibility that smaller, often privately-owned, pharmacies take greater risks with drug procurement than larger organizations, which are often franchises or major pharmacy chains.

In a just-published op-ed in the New York Times, American Enterprise Institute (AEI) international health economist Roger Bate highlights a better way to fight fake pharmaceuticals while still giving poor Americans access to less costly drugs from online pharmacies.